MAPT and Alzheimer disease: Notably, plasma p‐tau217 demonstrated a strong capacity for differentiating between Aβ/tau stages; abnormal plasma GFAP appeared to facilitate Aβ‐induced tau progression, whereas plasma NfL wa more closely associated with non‐AD‐specific neuronal injury and cognitive decline.